Acorda Therapeutics Inc (ACORQ)
0.80
-0.05
(-5.88%)
USD |
OTCM |
May 06, 16:00
Acorda Therapeutics Enterprise Value: 157.16M for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 157.16M |
| May 03, 2024 | 157.22M |
| May 02, 2024 | 157.22M |
| May 01, 2024 | 157.22M |
| April 30, 2024 | 157.03M |
| April 29, 2024 | 157.28M |
| April 26, 2024 | 157.07M |
| April 25, 2024 | 157.10M |
| April 24, 2024 | 156.85M |
| April 23, 2024 | 156.81M |
| April 22, 2024 | 156.74M |
| April 19, 2024 | 156.71M |
| April 18, 2024 | 156.64M |
| April 17, 2024 | 156.59M |
| April 16, 2024 | 156.64M |
| April 15, 2024 | 156.66M |
| April 12, 2024 | 156.71M |
| April 11, 2024 | 156.98M |
| April 10, 2024 | 157.26M |
| April 09, 2024 | 157.43M |
| April 08, 2024 | 157.65M |
| April 05, 2024 | 157.84M |
| April 04, 2024 | 158.25M |
| April 03, 2024 | 158.64M |
| April 02, 2024 | 159.27M |
| Date | Value |
|---|---|
| April 01, 2024 | 172.90M |
| March 28, 2024 | 172.57M |
| March 27, 2024 | 170.96M |
| March 26, 2024 | 171.19M |
| March 25, 2024 | 171.44M |
| March 22, 2024 | 171.19M |
| March 21, 2024 | 171.21M |
| March 20, 2024 | 171.69M |
| March 19, 2024 | 172.62M |
| March 18, 2024 | 172.93M |
| March 15, 2024 | 171.57M |
| March 14, 2024 | 172.24M |
| March 13, 2024 | 171.57M |
| March 12, 2024 | 171.89M |
| March 11, 2024 | 171.07M |
| March 08, 2024 | 172.05M |
| March 07, 2024 | 173.13M |
| March 06, 2024 | 172.68M |
| March 05, 2024 | 172.31M |
| March 04, 2024 | 172.32M |
| March 01, 2024 | 173.80M |
| February 29, 2024 | 173.06M |
| February 28, 2024 | 173.06M |
| February 27, 2024 | 172.81M |
| February 26, 2024 | 174.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
130.30M
Minimum
Mar 18 2020
568.76M
Maximum
May 08 2019
188.80M
Average
173.43M
Median
Feb 20 2024
Enterprise Value Benchmarks
| BioSig Technologies Inc | 15.74M |
| Verve Therapeutics Inc | -87.11M |
| Spectral AI Inc | 21.08M |
| AIM ImmunoTech Inc | 8.578M |
| Protalix BioTherapeutics Inc | 56.78M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -217.76M |
| Revenue (Quarterly) | 37.98M |
| Total Expenses (Quarterly) | 36.50M |
| EPS Diluted (Quarterly) | -175.32 |
| Gross Profit Margin (Quarterly) | 85.26% |
| Profit Margin (Quarterly) | -573.3% |
| Earnings Yield | -25.48K% |
| Normalized Earnings Yield | -4795.36 |